Gráfico Histórico do Ativo
6 Meses : De Abr 2019 até Out 2019
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Monday that a phase 3 study of its cancer drug niraparib, which is marketed under the name Zejula, yielded positive results.
The drug demonstrated a statistically-meaningful improvement in survival without disease progression in women with ovarian cancer, regardless of their biomarker status, the British pharmaceutical company said.
Safety results were consistent with previous clinical trials. The medication was being administered as a first-line maintenance treatment following platinum based chemotherapy.
GlaxoSmithKline said full results from the study, called Prima, will be made public at an upcoming scientific meeting.
Write to Carlo Martuscelli at email@example.com
(END) Dow Jones Newswires
July 15, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.